Американское общество гирудотерапии

Challenging Argatroban Management of a Child on Extracorporeal Support and Subsequent Heart Transplant

Research article published in Seminars in cardiothoracic and vascular anesthesia (2015)

Последнее обновление: June 18, 2026Рецензент: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Case reportРазработка лекарственных препаратовLatham GJ et al. · Seminars in cardiothoracic and vascular anesthesia, 2015

Abstract

A 6-year-old child developed heparin-induced thrombocytopenia while on extracorporeal life support. Hours after a difficult transition from heparin to argatroban for anticoagulation therapy, the child underwent heart transplantation. Intraoperative management was plagued with circuit thrombus formation while on cardiopulmonary bypass and subsequent massive hemorrhage after bypass. We review the child's anticoagulation management, clinical challenges encountered, and review current literature related to the use of argatroban in pediatric cardiac surgery.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeCase ReportsJournal Article
Indexed MeSH termsAntithrombinsArginineCardiopulmonary BypassChildExchange Transfusion, Whole BloodExtracorporeal Membrane OxygenationHeart TransplantationHeparinHirudinsHumansMalePeptide Fragments

Резюме

Challenging Argatroban Management of a Child on Extracorporeal Support and Subsequent Heart Transplant.

Почему это важно для гирудотерапии

This case report details the anticoagulation management of a 6-year-old child who developed heparin-induced thrombocytopenia while on extracorporeal life support and subsequently underwent heart transplantation. The authors describe a difficult transition from heparin to argatroban, complicated by intraoperative circuit thrombus formation during cardiopulmonary bypass and subsequent massive hemorrhage, along with a review of current literature on argatroban in pediatric cardiac surgery. The abstract makes no mention of leeches, hirudin, direct thrombin inhibitors as a class, or any hirudotherapy-related content. No defensible ASH relevance exists based on this abstract. The study is limited to a single patient's clinical course with no leech-derived therapy involved.

Цитирование

Challenging Argatroban Management of a Child on Extracorporeal Support and Subsequent Heart Transplant

Latham GJ et al. · Seminars in cardiothoracic and vascular anesthesia, 2015

DOI

Связанный клинический контекст

Узнайте, как это исследование связано с клинической практикой

Drug PipelineDrug DevelopmentDirect Thrombin InhibitorsHirudinAnticoagulation CompoundsHemostasisOtolaryngology

Добавлено в библиотеку ASH: May 27, 2026 · Последнее обновление сайта: June 18, 2026

Этот сайт предоставляет образовательную информацию и не является медицинской консультацией, диагнозом или рекомендацией по лечению. Гирудотерапия сопряжена с клинически значимыми рисками и должна проводиться только квалифицированными клиницистами в рамках институционально утверждённых протоколов. Разрешение FDA 510(k) для медицинских пиявок ограничено определёнными показаниями; обсуждения исследовательского и нелицензионного применения отмечены соответствующим образом. Для индивидуальных медицинских рекомендаций обратитесь к квалифицированному медицинскому специалисту.